Synonyms: SNDX-5613 | SNDX5613
Compound class:
Synthetic organic
Comment: The chemical structure for revumenib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as an antineoplastic agent. It resolved to Syndax Pharmaceuticals' SNDX-5613 via a PubChem match on SMILES. SNDX-5613 inhbits the Menin-MLL protein-protein interaction, as a strategy that's being investigated to treat MLL-rearranged leukemias (such as ALL and AML) [1]. Menin inhibitors promote differentiation and apoptosis of MLL-rearranged AML cells in vitro.
|
|
No information available. |
Summary of Clinical Use |
Revumenib (SNDX-5613) has been advanced to early stage clinical evaluation. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04065399 | A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/Phase 2 Interventional | Syndax Pharmaceuticals |